Scientific Advisory Board
Professor Margaret Frame OBE, PhD
Science Director Cancer Research UK Edinburgh Centre and and Chair of Cancer Biology, University of Edinburgh.
Professor Frame has spent years working on a specialised molecular network that’s responsible for controlling how cells stick to one another, move and spread. She’s found that a key molecule in this so-called ‘adhesion network’, called FAK, can affect the environment around tumours and help the cancer cells escape attack by the immune system.
Professor Neil Carragher PhD
Personal Chair of Drug Discovery, Cancer Research UK Edinburgh Centre
Professor Carragher has been the principal Investigator of Drug Discovery at the University of Edinburgh since 2010 after spending time in industry as Principal Scientist with the Advanced Science and Technology Laboratory at AstraZeneca. The Edinburgh Drug Discovery group embraces advanced technology platforms and disease models to drive innovations in oncology drug discovery and development.
Alan Serrels PhD
Research Fellow, Cancer Research UK Edinburgh Centre
Dr Serrels work focuses on how cancer cells contribute to regulating the composition of the tumour immune environment to promote evasion of the anti-tumour immune response. His team recently identified a new role for the adhesion linked kinase Focal Adhesion Kinase (FAK) in regulating chemokine and cytokine expression in cancer cells. Their aim is to identify optimal combinations with current / emerging immunotherapies for translation to the clinic.
Professor Paul Timpson PhD
Laboratory Head - Invasion and Metastasis Lab
Paul completed his PhD at the Beatson Institute for Cancer Research, UK in 2002 before moving to the Garvan Institute in 2003 to investigate growth factor receptor trafficking in breast cancer and head and neck cancers. Today, Paul’s laboratory has an ongoing interest in the development of novel multi-disciplinary live imaging techniques to investigate molecular dynamics of cancer cells in vivo and using these techniques to understand cancer in the context of the surrounding environment. Pinpointing the molecular drivers of cancer progression and the environmental cues that cause resistance to current therapies are the focus of his group’s research.